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Abstract
Background: There is a clear need for novel approaches to malaria vaccine development. We aimed to develop a
genetically attenuated blood-stage vaccine and test its safety, infectivity, and immunogenicity in healthy volunteers.
Our approach was to target the gene encoding the knob-associated histidine-rich protein (KAHRP), which is
responsible for the assembly of knob structures at the infected erythrocyte surface. Knobs are required for correct
display of the polymorphic adhesion ligand P. falciparum erythrocyte membrane protein 1 (PfEMP1), a key virulence
determinant encoded by a repertoire of var genes.
Methods: The gene encoding KAHRP was deleted from P. falciparum 3D7 and a master cell bank was produced in
accordance with Good Manufacturing Practice. Eight malaria naïve males were intravenously inoculated (day 0) with
1800 (2 subjects), 1.8 × 105 (2 subjects), or 3 × 106 viable parasites (4 subjects). Parasitemia was measured using
qPCR; immunogenicity was determined using standard assays. Parasites were rescued into culture for in vitro
analyses (genome sequencing, cytoadhesion assays, scanning electron microscopy, var gene expression).
Results: None of the subjects who were administered with 1800 or 1.8 × 105 parasites developed parasitemia; 3/4
subjects administered 3× 106 parasites developed significant parasitemia, first detected on days 13, 18, and 22. One
of these three subjects developed symptoms of malaria simultaneously with influenza B (day 17; 14,022 parasites/
mL); one subject developed mild symptoms on day 28 (19,956 parasites/mL); and one subject remained
asymptomatic up to day 35 (5046 parasites/mL). Parasitemia rapidly cleared with artemether/lumefantrine.
Parasitemia induced a parasite-specific antibody and cell-mediated immune response. Parasites cultured ex vivo
exhibited genotypic and phenotypic properties similar to inoculated parasites, although the var gene expression
profile changed during growth in vivo.
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Conclusions: This study represents the first clinical investigation of a genetically attenuated blood-stage human
malaria vaccine. A P. falciparum 3D7 kahrp– strain was tested in vivo and found to be immunogenic but can lead
to patent parasitemia at high doses.
Trial registration: Australian New Zealand Clinical Trials Registry (number: ACTRN12617000824369; date: 06 June
2017).
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Background
There is currently a strong commitment to eradicate
malaria in the 21st century. This ambitious goal will be
facilitated by the development of an effective vaccine.
The past 20 years have seen over 100 clinical trials of
malaria vaccine candidates, with the vast majority testing
sub-unit vaccines [1]. To date, only one vaccine (RTS,S/
AS01) has demonstrated protective efficacy against clin-
ical malaria in a phase 3 trial, although protection is only
partial [2]. RTS,S/AS01 has been approved by the Euro-
pean Medicines Agency, and a pilot implementation
program coordinated by the World Health Organization
is underway in Africa [3]. Given the overall slow pro-
gress of current vaccine strategies, there is a clear need
for novel approaches.
Live, whole cell vaccines offer several potential advan-
tages over subunit vaccines against a range of pathogens
including malaria parasites. These include exposure to a
greater range of antigens that are delivered to the cor-
rect anatomical compartments for immunological prim-
ing, as well as providing the correct pattern recognition
signals to the immune system, which are specific for the
pathogen class [4]. Various whole sporozoite vaccines
that target the pre-erythrocytic stage of malaria parasite
development have demonstrated promising results in
preclinical studies, human challenge studies, and in clin-
ical trials in malaria-endemic areas [1]. Strategies for
sporozoite attenuation have included the use of radiation
[5] or targeted gene deletion [6–8] to produce genetic-
ally attenuated parasites (GAP). Naturally acquired im-
munity to malaria is complex, with evidence suggesting
that repeated exposure to blood-stage infection is an im-
portant component and is associated with an antibody
response against merozoites and infected erythrocytes
[9]. However, in the modern era, only a single live whole
parasite blood-stage vaccine candidate has been tested in
humans, in a pilot study undertaken using chemically at-
tenuated parasites [10]. We aimed to develop a blood-
stage GAP malaria vaccine and characterize its safety, in-
fectivity, and immunogenicity in a phase 1 clinical trial.
P. falciparum erythrocyte membrane protein 1
(PfEMP1) is a polymorphic adhesion ligand displayed on
knob-like structures on the surface of P. falciparum-in-
fected erythrocytes, with specific types binding a variety
of host receptors present on the vascular endothelium
[11]. This arrangement facilitates attachment and se-
questration of the infected erythrocyte in the microvas-
culature, thereby protecting parasites from clearance by
the spleen [12]. Further, parasite sequestration is a crit-
ical determinant of malaria pathogenesis as it leads to
the accumulation of infected erythrocytes in vital organs
[13]. PfEMP1 is also a target of protective immunity [14]
and has been shown to have an immunomodulatory ef-
fect [15]. PfEMP1 is a variable surface antigen, encoded
by a repertoire of around 60 var genes per genome [16].
Thus, creation of a genetically modified parasite lacking
PfEMP1 would require a targeted genetic modification
that would prevent transcription of any var gene allele,
an approach that may be technically challenging. Fur-
ther, if such a result were achieved it would result in no
expression of PfEMP1, a protein which has been pro-
posed to be the target of strain-specific immunity [14].
The in vivo virulence and immunogenicity of a knob-
less P. falciparum clone selected under in vitro culture
was investigated in Aotus monkeys by Langreth and Pe-
terson [17]. After multiple inoculations with the knob-
less parasites, non-splenectomized animals either did not
develop patent parasitemia, or exhibited very low para-
sitemia, with infections self-resolving. In contrast, sple-
nectomized animals developed significant infections
when inoculated with knobless parasites. This study in-
dicated the importance of the knobs on the surface of
infected erythrocytes in enabling parasites to sequester
to avoid splenic clearance. When monkeys with intact
spleens were exposed to knobless parasites they devel-
oped a humoral immune response and exhibited partial
protection when subsequently challenged with knob-
positive parasites. Together, these data suggest a knob-
minus live malaria vaccine represents an attractive
approach.
Our approach to develop a blood-stage GAP vaccine
was to target the gene encoding the knob-associated
histidine-rich protein (KAHRP), which is responsible for
the assembly of knob structures at the infected erythro-
cyte surface. In the absence of KAHRP, P. falciparum-in-
fected erythrocytes lack knob-structures and cannot
correctly display PfEMP1 [18]. Building on the early
studies in Aotus monkeys, we hypothesized that the loss
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of KAHRP would result in a significant loss of fitness
in vivo due to enhanced parasite clearance accompanied
by priming of the immune system from lack of parasite
sequestration and increased passage to the spleen. The
production of the blood-stage GAP vaccine under Good
Manufacturing Practice (GMP) by targeted deletion of
the gene encoding KAHRP has been described previ-
ously [19]. Here we report the results of a clinical trial to
characterize the safety, infectivity, and immunogenicity
of the P. falciparum kahrp– blood-stage GAP vaccine in
healthy volunteers.
Methods
Study design and participants
This phase 1 study was planned to be composed of two
parts. The first part, performed as planned, was an open-
label, dose-escalation study to determine the safety, infect-
ivity, and immunogenicity of single doses of the GAP vac-
cine administered intravenously. The second part was
planned to provide preliminary information on the effi-
cacy of the GAP vaccine by determining the protective
immune response of GAP vaccination to subsequent chal-
lenge with wild-type blood-stage P. falciparum. However,
it was decided not to proceed with the second part due to
the lack of complete attenuation of the GAP vaccine, and
alloimmunization events, observed in the first part (see
the “Results” section). The study design and methodology
for the second part of the study are not described here.
Healthy malaria naïve males aged 18 to 55 years were
eligible for inclusion in the study (for full eligibility cri-
teria see Additional File 1: Text S1). The study was con-
ducted at Q-Pharm (Brisbane, Australia) and was
registered on the Australian and New Zealand Clinical
Trials Registry (Trial ID: ACTRN12617000824369; date
registered: 06 June 2017).
GAP vaccine
The manufacture of the GAP vaccine has been described
previously [19]. Briefly, genetically attenuated blood-
stage malaria parasites were produced by targeted dele-
tion of kahrp from P. falciparum strain 3D7, and para-
sites were cultured in a wave bioreactor under GMP-
compliant conditions. The cryopreserved GAP master
cell bank was tested for sterility, absence of viral con-
taminants and endotoxins, and parasite identity, viability,
and antimalarial drug sensitivity. The GAP master cell
bank has a parasitemia of 6.3% with 96% of parasites at
ring stage. The GAP vaccine inoculum used for each
subject in this study was prepared aseptically from a sin-
gle vial of the GAP master cell bank by thawing, wash-
ing, and suspending the appropriate number of infected
erythrocytes in 0.9% sodium chloride for injection in a
final volume of 2 mL. Syringes containing the inocula
were stored at a controlled temperature for a maximum
of 2 h before administration.
Procedures
The study was conducted in four consecutive dose co-
horts of two subjects each. Sample size was not based on
formal statistical calculations but was considered appro-
priate to achieve the study objectives. Following a
screening period of up to 28 days, subjects were inocu-
lated intravenously with the GAP vaccine (day 0). A sen-
tinel dosing strategy was used for the first three cohorts
whereby the first subject in each cohort was inoculated
with the GAP vaccine at least 24 h before the second
subject. Subjects in cohort 4 were inoculated with the
GAP vaccine concurrently since no significant safety sig-
nals had been observed in the preceding cohorts.
Parasitemia was monitored throughout the study by
collecting blood samples and performing quantitative
PCR (qPCR) targeting the gene encoding P. falciparum
18S rRNA [20]. Subjects were to receive a standard cura-
tive course of artemether/lumefantrine treatment if para-
sitemia reached ≥5000 parasites/mL (≥200,000 parasites/
mL for cohort 4) or if clinical symptoms of malaria were
observed (clinical symptom score > 6), or on day 28±3
(day 60±3 for cohort 4) if the preceding treatment cri-
teria had not been reached earlier. The end of the study
visit occurred on day 90 for safety and immunogenicity
assessments.
The GAP vaccine dose administered to cohort 1 was
1800 viable parasites which is the dose of P. falciparum
3D7 wild-type parasites routinely used in previous con-
trolled human malaria infection (CHMI) studies using
the induced blood-stage malaria (IBSM) model [21–23].
A formal Safety Review Team meeting was conducted
between cohorts to assess the safety of the GAP vaccine
and decide whether to dose escalate and proceed with
the next cohort. The planned dose escalation was 1.8 ×
105 viable parasites for cohort 2 (100-fold increase from
cohort 1) and 3 × 106 viable parasites for cohort 3 (a
dose of parasites equivalent to that released from the
liver after a five mosquito bite CHMI study [24]). Based
on the results observed in cohort 3 (with both subjects
developing parasitemia but remaining asymptomatic),
the study protocol was amended to include a fourth co-
hort administered the same GAP vaccine dose as cohort
3 (3 × 106 viable parasites), but with the antimalarial
treatment criteria amended with a longer follow-up to
allow for better characterization of parasite infectivity. A
planned protocol deviation was performed for cohort 3
due to the unexpected results observed; subject 6 was
administered antimalarial treatment on day 35 when
parasitemia reached 5000 parasites/mL instead of the
protocol stipulated day 28. This was considered reason-
able since the subject was asymptomatic and consented
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to the additional period of follow-up. The QIMR Ber-
ghofer Medical Research Institute Human Research Eth-
ics Committee was notified of this decision.
Safety assessments
Safety assessments were performed throughout the study
and included adverse event (AE) recording, physical ex-
aminations, vital signs monitoring, electrocardiographs
(ECGs), clinical laboratory evaluation (hematology, bio-
chemistry, and urinalysis), and malaria clinical score re-
cording [25]. The severity of AEs was graded according
to a set of criteria developed for guidance of commonly
reported symptoms, signs, and abnormal laboratory find-
ings in malaria challenge studies (mild = grade 1; moder-
ate = grade 2; severe = grade 3). These were adapted
from the Common Terminology Criteria for Adverse
Events v3.0 [26].
Immunogenicity assessments
The development of an antibody response to the GAP
vaccine was determined by collecting blood samples
and using standard ELISA methods to measure IgG
and IgM antibodies towards P. falciparum merozoite
surface protein 2 (MSP2) and to whole parasite lysate
(Additional File 2: Text S1) [27, 28]. The development
of a cell-mediated immune response to the GAP vac-
cine (cohorts 1-3 only) was determined by collecting
blood samples and using flow cytometry to identify T
cell subsets (Additional File 2: Text S2, Table S1, and
Figure S1) [29, 30].
In vitro analysis of parasites rescued into culture
A series of in vitro analyses were performed on parasites
isolated from the blood of subjects at maximum parasit-
emia prior to antimalarial treatment. Parasites were cul-
tured directly from blood samples to reach a target
parasitemia of 2-8% with > 50% ring stage parasites be-
fore cryopreservation. The properties of the isolated par-
asites were compared to parasites inoculated on day 0.
Genotyping of the parasite genetic material was per-
formed using standard molecular biology techniques in-
cluding Sanger sequencing and whole genome
sequencing (Additional File 3: Text S1) [31–36]. The
cytoadherence phenotype of the isolates was determined
using both static and flow adhesion assays (Additional
File 3: Text S2) [37, 38]. Scanning electron microscopy
was performed to characterize the knob status of
parasite-infected erythrocytes (Additional File 3: Text
S3) [39]. The var gene expression profile of parasites
was determined using diagnostic RT-PCR (Additional
File 3: Text S4 and Table S1) [40–43].
Results
Subjects
The study was conducted from 6 July 2017 to 11 Sep-
tember 2019. A total of 8 subjects were enrolled over
four dose cohorts (Fig. 1). Subjects were healthy malaria-
naïve males between the ages of 18 and 48 years; five
subjects self-selected their race as White, two as Latin
Hispanic, and one as Australian Aboriginal (Table 1). All
subjects completed the study and were included in the
analysis of study endpoints.
GAP vaccine infectivity
Parasitemia was not detected in subjects in cohort 1 (ad-
ministered 1800 viable parasites) or cohort 2 (adminis-
tered 1.8 × 105 viable parasites) at any time-point during
the study (Fig. 2). Parasitemia was detected in all four
subjects in cohorts 3 and 4 (administered 3× 106 para-
sites), although parasitemia was only detected very
briefly and at a very low level (around the limit of detec-
tion) in one of these subjects (subject 8, day 1 and day
38, maximum 3 parasites/mL). The other three subjects
developed significant parasitemia, the progression of
which was highly variable between subjects. Antimalarial
treatment with artemether/lumefantrine was initiated on
day 17, day 28, and day 35 for these subjects at a parasit-
emia of 14,022 parasites/mL, 19,956 parasites/mL, and
5151 parasites/mL, respectively (Fig. 2, arrows). Parasit-
emia was rapidly cleared following artemether/lumefan-
trine treatment and no recrudescence was observed up
to day 90 (Fig. 2).
Fig. 1 Trial profile. Volunteers meeting the eligibility criteria were
enrolled in one of four GAP vaccine dose cohorts. Dose escalation
was performed in cohorts 1 to 3; cohort 4 received the same dose
as cohort 3
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Safety
A total of 44 adverse events (AEs) were reported in this
study, the majority of which were of mild severity (Table 2
and Additional File 1: Table S1). One AE met the
protocol-defined criteria of a serious adverse event: a sub-
ject in cohort 4 experienced a joint dislocation on day 70
which required hospitalization and surgery. This event
was not considered related to any study interventions.
There were 15 AEs in 3 subjects (all administered the
highest dose of 3 × 106 viable parasites) that were consid-
ered to be possibly related to the GAP vaccine. Twelve of
these AEs occurred in one subject (subject 7) and were
mild symptoms/signs frequently associated with malaria
(headache [2 events], myalgia, arthralgia [2 events], mal-
aise, chills, pyrexia [2 events, maximum body temperature
38.9 °C], tachycardia [maximum heart rate 108 beats per
minute], feeling hot, hyperhidrosis). However, this subject
was confirmed by PCR to be positive for influenza B at the
time of antimalarial treatment (which coincided with the
onset of the majority of the signs/symptoms listed above);
thus the symptoms and signs observed may not have been
malaria-related. Another subject (subject 5) experienced
mild fatigue (24 h duration) which was considered possibly
related to the GAP vaccine.
Alloimmunization to minor erythrocyte antigens was
observed in two subjects (subject 7 and subject 8) at the
end of the study visit on day 90, which was considered
related to the GAP vaccine. Subject 7 developed low titer
anti-C and anti-P1 antibodies, while subject 8 developed
low titer anti-c antibodies. Retrospective testing was per-
formed on blood samples collected on day 21 (subject 7)
and day 31 (subject 8). Subject 7 was positive for anti-P1
on day 21 (there was an insufficient sample to test for
anti-C at this time point); subject 8 was negative for
anti-c on day 31. The blood group and phenotype of
these subjects, as well as the donor red blood cells used
to manufacture the GAP master cell bank, are presented
in Additional File 1: Table S2. Alloimmunization was
not observed in any of the other 6 subjects administered
the GAP vaccine.
Immunogenicity
The three subjects who developed significant parasitemia
following administration of 3 × 106 parasites (subject 5,
subject 6, and subject 7) also developed a malaria-specific
antibody response. The antibody response to a key im-
munogenic blood-stage antigen (MSP2) was measured.
The timing of the anti-MSP2 IgG response (Fig. 3A) and
IgM response (Additional File 2: Figure S2) appeared to
correlate with the development of parasitemia (Fig. 2). IgG
and IgM antibody responses to whole parasite lysate were
comparable to the MSP2 response in all subjects (Add-
itional File 2: Figure S3). Furthermore, a malaria-specific
Table 1 Demographic profile of subjects
Cohort 1 Cohort 2 Cohort 3 Cohort 4
Subject 1 Subject 2 Subject 3 Subject 4 Subject 5 Subject 6 Subject 7 Subject 8
GAP vaccine dose (viable parasites) 1800 1.8×105 3×106 3×106
Age (years) 40 48 26 19 32 18 29 20
Sex Male Male Male Male Male Male Male Male
Race Latin Hispanic Latin Hispanic White Australian Aboriginal White White White White
Body mass index (kg/m2) 23.0 27.3 18.1 21.7 26.7 23.8 26.8 23.0
BMI body mass index
Fig. 2 Infectivity of the GAP vaccine. Parasitemia was monitored by
collecting blood samples and performing qPCR targeting the gene
encoding P. falciparum 18S rRNA. Arrows indicate the commencement
of treatment with artemether/lumefantrine for subjects who
developed parasitemia. Time points at which parasitemia could not be
detected were substituted with a value of 1 parasite/mL for the
purpose of graphing on a logarithmic scale. Subject 7 was confirmed
to be positive for influenza B at the time of antimalarial treatment
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cell-mediated immune response to the GAP vaccine was
identified in two of the three subjects (subject 5 and sub-
ject 6; not tested in subject 7) administered 3× 106 para-
sites, including increased expression of activation markers
PD-1 and ICOS on Th1-like Tfh cells (Fig. 3B) and in the
expression of activation markers CD38 and HLA-DR on
Th1 cells (Fig. 3C) on day 28. There was no change in the
frequencies of CD4+ T cells, Treg cells, Th1 cells, or Tfh
cells in the peripheral blood of any of the subjects over the
course of the study (Additional File 2: Figure S4).
In vitro analyses of parasites rescued into culture
In vitro analyses of parasites rescued into culture from
blood samples collected at peak parasitemia were per-
formed to determine if any genotypic or phenotypic
changes occurred during growth in vivo. Whole genome
sequencing revealed that there were no significant gen-
etic changes between the inoculated parasites and the
ex vivo isolates (Additional File 3: Text S5), confirming
that parasites had not reverted to a wild-type genotype,
and had not acquired new mutations that may







Cohort 4b (N=2) Total
(N=8)
Number of subjects with at least one adverse event [n (%)]; number of adverse events
Any adverse event 2 (100%); 13 1 (50%); 3 2 (100%); 5 2 (100%); 23 7 (87.5%); 44
Adverse event of moderate intensity 1 (50%); 3 0 (0%); 0 1 (50%); 1 2 (100%); 3 4 (50%); 7
Adverse event of severe intensity 0 (0%); 0 0 (0%); 0 0 (0%); 0 1 (50%); 1a 1 (12.5%); 1a
Adverse event related to GAP vaccine 0 (0%); 0 0 (0%); 0 1 (50%); 1 2 (100%); 14 3 (37.5%); 15
Serious adverse event 0 (0%); 0 0 (0%); 0 0 (0%); 0 1 (50%); 1a 1 (12.5%); 1a
aThe severe adverse event (joint dislocation) also met the criteria for a serious adverse event since it required hospitalization and surgery. This event was not
considered related to the GAP vaccine. bOne subject in cohort 4 (subject 7) was confirmed to be positive for influenza B at the time of antimalarial treatment
Fig. 3 Immunogenicity of the GAP vaccine. The parasite-specific antibody response was determined by collecting blood samples and measuring
anti-MSP2 IgG over the course of the study in each subject (A). The cell-mediated immune response was determined by measuring the
frequency of activated (PD-1+ ICOS+) CD4+ Tfh cells (B) and activated (CD38hi HLA-DR+) Th1 cells (C) in peripheral blood mononuclear cells over
the course of the study in each subject. CD4+ T cell subsets were identified in B and C as indicated in Additional File 2: Figure S1. The cell-
mediated immune response was not determined for cohort 4 (subject 7 and subject 8).
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compensate for KAHRP deficiency. The ex vivo parasite-
infected erythrocytes showed the same knob-minus ap-
pearance as infected erythrocytes inoculated on day 0
when examined using scanning electron microscopy
(Fig. 4 and Additional File 3: Text S6) and retained an
impaired cytoadherence phenotype in static and flow ad-
hesion assays (Fig. 5 and Additional File 3: Text S7). Fol-
lowing growth in vivo, parasites switched away from
primarily expressing a single group C var gene at base-
line (inoculation), to elevated expression of most of the
var repertoire in two subjects (subject 5 and subject 6)
and a less broad but still fairly diverse pattern of expres-
sion in subject 7 (Fig. 6 and Additional File 3: Text S8).
The most abundantly transcribed genes differed between
the subjects and none had a published association with
virulence (Additional File 3: Table S2) [44]. Wild-type P.
falciparum 3D7 parasites from a CHMI study using the
IBSM model [45] were analyzed as a control. The wild-
type parasites used for inoculation of two subjects in
that study expressed much of the var repertoire at ele-
vated levels; the expressed repertoire following growth
in vivo was largely unchanged in one subject but was
less diverse in the other subject (Fig. 6).
Discussion
This study represents the first clinical investigation of a
genetically attenuated blood-stage human malaria vac-
cine. We demonstrate that P. falciparum 3D7 parasites
lacking KAHRP are highly attenuated in vivo compared
to their wild-type counterparts, with no parasitemia de-
tectable up to 28 days following inoculation of up to
1.8× 105 viable parasites. Inoculation of healthy subjects
with 1800–2800 wild-type P. falciparum 3D7 parasites
in CHMI studies using the IBSM model consistently re-
sults in detectable parasitemia within 5 days, and parasit-
emia typically reaches > 5000 parasites/mL 8 days after
inoculation [21, 22, 25, 46, 47]. However, we found that
P. falciparum kahrp– parasites were capable of generat-
ing a significant infection when administered at a high
dose (3 × 106 viable parasites).
The fact that P. falciparum kahrp– parasites are cap-
able of generating a significant infection in humans was
somewhat unexpected based on the well-characterized
role of KAHRP in mediating the adherence of infected
erythrocytes to the microvascular endothelium, which is
an important process in promoting parasite survival by
evading splenic clearance [18]. The in vivo growth ob-
served in the current study appears to be consistent with
the previously reported breakthrough infections (peak
parasitemia of 0.02%) observed in 2 of 7 Aotus monkeys
challenged with multiple doses of knobless P. falciparum
parasites (up to 1× 107 parasites) [17]. The delay in and
variability of timing of onset of patent parasitemia in the
subjects administered the highest dose suggests some
in vivo adaptation of parasites to enable escape from
host clearance mechanisms. In contrast to the highly re-
producible growth pattern of parasites seen in experi-
mental infection with unattenuated P. falciparum 3D7
parasites [48], there appears to be significant inter-
individual variability in this process. Such variability
would likely complicate any use of this approach for
in vivo immunization. Because of the unexpected break-
through in blood stage infection at the highest dose, we
investigated for selection of phenotypic or genetic
changes that had taken place to explain this observation.
Genome sequencing of parasites rescued into culture at
maximum parasitemia prior to antimalarial treatment
confirmed that parasites had not reverted back to wild-
type. Similarly, ex vivo cultured parasites retained their
knob-minus phenotype, and exhibited impaired cytoad-
herence, particularly under flow conditions.
There was evidence that parasites switched their ex-
pression of var genes during in vivo growth. Parasites
administered to subjects on day 0 expressed a single
dominant group C var gene. This is consistent with pre-
vious evidence that, in the absence of phenotype selec-
tion, parasites often switch to expression of a group C
var gene which appear to have a slower rate of silencing
than other var gene types [49]. Following growth in vivo,
parasites had switched away from the expression of the
Fig. 4 Scanning electron microscopy of parasite-infected erythrocytes. P. falciparum 3D7 wild-type (A), P. falciparum 3D7 kahrp– prior to
inoculation (B), P. falciparum 3D7 kahrp– cultured ex vivo from subject 5 (C) and P. falciparum 3D7 kahrp– cultured ex vivo from subject 6 (D).
Scale bar = 1 μm
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single group C var gene, suggesting selection in the
naïve, human host, possibly for an adhesion phenotype.
The increased diversity of var expression could also re-
flect the absence of selection for cytoadhesive variants,
because the infected erythrocytes could not cytoadhere.
If this were the case, then the altered environment
within the host stimulated the de-repression of much of
the var repertoire. Interestingly a similar observation of
broad var de-repression has been made in CHMI studies
using sporozoites [40]. In that case, passage through
mosquitoes was inferred to have reset the epigenetic
regulation of var genes, consistent with the broad, epi-
genetic reprogramming that occurs through sexual
reproduction in higher order eukaryotes. The data we
present suggests that the human host environment itself
may stimulate var gene de-repression during the para-
site’s asexual lifecycle.
Despite the well-characterized role of knobs in the
cytoadherence and sequestration of parasite-infected
erythrocytes, there is some evidence that erythrocytes in-
fected with knob-minus parasites may be capable of
binding weakly to the microvascular endothelium. Knob-
less P. falciparum clones were found to adhere to CD36
at a level comparable to the parent 3D7 strain under
static conditions, but dramatic differences were observed
under flow conditions [18]. Similar results were observed
in the current study, with P. falciparum kahrp– parasites
exhibiting some adhesion to CD36 under static condi-
tions (albeit at considerably lower levels than the control
strain) and almost no binding under flow conditions.
These results are supported by recent research using
engineered human capillaries which demonstrated that
erythrocytes infected with knob-minus parasites can ac-
cumulate in the post-capillary space where shear rates
are lower [50]. In contrast, knob-positive parasite-
infected erythrocytes that were trypsinized to remove
the surface presentation of PfEMP1 did not accumulate
in vessels to any extent. Thus, we hypothesize that in the
current study a limited number of P. falciparum kahrp–
parasites were able to bind to the microvascular endo-
thelium in areas where shear rates were low and avoid
splenic clearance. This may have been facilitated by the
switch in var gene expression observed during in vivo
Fig. 5 Cytoadherence of parasite-infected erythrocytes. The binding of
infected erythrocytes to purified ICAM-1 (A) and CD36 (B) was determined
under static conditions, and binding to unstimulated (○) or TNF-stimulated (●)
human dermal microvascular endothelial cells (HDMEC) was determined
under flow conditions (C). Assays were performed as described in Additional
File 3: Text S2. Shown are the mean ± SD for 4 independent experiments. P.
falciparum 3D7 kahrp– parasites cultured ex vivo from subject 5 and subject 6
were compared with parasites inoculated on day 0. There was no difference
in cytoadherence characteristics when significance was determined by
unpaired t test with Welch’s correction (P >0.05). The laboratory isolate P.
falciparum ItG was used as a positive control. IE: infected erythrocytes
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growth to present a range of PfEMP1s on the cell sur-
face. An alternative hypothesis is that parasites may have
accumulated in the spleen and were cleared by the im-
mune system slowly enough to maintain an infection.
Immunogenicity results indicated that the GAP vac-
cine was capable of eliciting a malaria-specific antibody
and cell-mediated immune response when administered
at the highest dose (3 × 106 viable parasites).
Immunogenicity appeared to be dependent on parasite
replication, evidenced by the fact that the subject admin-
istered the highest dose who did not develop parasitemia
failed to generate a detectable antibody response. This
finding may be consistent with evidence that killed
whole parasite malaria vaccines require an adjuvant to
induce robust immunity [51]. The anti-parasite humoral
immune responses to the immunodominant blood-stage
Fig. 6 Var gene expression profiles. Log2 fold change in var transcript copy number relative to single copies in P. falciparum 3D7 gDNA. P. falciparum 3D7
kahrp– parasites cultured ex vivo from three subjects (kahrp– subject 5, kahrp– subject 6, and kahrp– subject 7) were compared with two replicates of parasites
inoculated on day 0 (kahrp– pre inoc.1 and kahrp– pre inoc.2). Parasites were collected from subjects by taking blood samples immediately prior to antimalarial
treatment initiation; three replicate samples were collected from subject 7 (kahrp– subject 7.1, kahrp– subject 7.2 and kahrp– subject 7.3). The duration of in vitro
culture for each sample is specified in Additional File 3: Table S1. As a control, wild-type P. falciparum 3D7 parasites cultured ex vivo from two subjects (WT
subject 1 and WT subject 2) in a controlled human malaria infection study using the induced blood stage malaria model [45] were compared with parasites
inoculated on day 0 (WT pre inoc.). Blue bars indicate high expression, red bars indicate low expression, and black bars indicate that no expression was
detected. Rows list var gene group and accession numbers
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antigen MSP2 in this study were similar to those seen
during natural infection against this and other blood-
stage antigens, as well as when they were measured in
CHMI studies using the IBSM model where subjects
were infected with wild-type 3D7 parasites [52, 53]. As
the preclinical primate data suggest a critical role of the
spleen in the outcome of infection with knobless para-
sites, the effect of splenectomy on immunogenicity and
clearance phenotype would require careful investigation
in future clinical studies.
Although no serious safety concerns prevented com-
pletion of this stage of clinical development of the
candidate vaccine, two considerations resulted in the
vaccine not progressing to testing for protective effi-
cacy in a challenge study with unattenuated parasites.
Firstly, the fact that an immune response only devel-
oped in subjects who developed patent parasitemia
some weeks after inoculation, and this parasitemia re-
quired termination by timed antimalarial chemother-
apy, would impose significant practical limitations on
the clinical development of this vaccine in the ab-
sence of other modifications to render the parasite
avirulent. Secondly, two subjects administered the
highest dose of GAP vaccine developed erythrocyte
alloimmunization (anti-C and anti-P1 antibodies in
one subject and anti-c antibodies in the other sub-
ject). This was unexpected based on our previous ex-
perience with CHMI studies using the IBSM model
where alloimmunization attributed to the malaria
challenge agent has not been reported previously (ap-
proximately 400 subjects in 32 studies). The fact that
alloimmunization was observed in subjects who were
administered a dose of parasites approximately 1000-
fold higher than is typically administered in CHMI
studies using the IBSM model involving wild-type P.
falciparum 3D7 (3× 106 viable parasites vs 2800 viable
parasites) suggests that the dose of parasitized eryth-
rocytes may be a factor. The total dose of erythro-
cytes (including non-parasitized) administered was
similar to that routinely administered (approximately
1 × 108 erythrocytes). We speculate that altered anti-
gen presentation by parasitized erythrocytes with in-
creased passage to the spleen may contribute to a
higher probability of alloimmunization with the GAP
vaccine. Of note, one of the 8 subjects administered a
chemically attenuated blood-stage P. falciparum para-
site vaccine in a pilot study also developed anti-c al-
loantibodies [10]. Although anti-P1 antibodies are not
considered clinically important for transfusion reac-
tions, anti-C and anti-c antibodies may result in a de-
layed transfusion reaction characterized by slow drop
in hemoglobin over two weeks post-transfusion. Con-
sultation with transfusion medicine specialists indi-
cated there is no immediate risk if these subjects
were to require emergency administration of un-
matched Group O Rh (D) negative blood, and in the
setting of routine blood transfusion a full cross-match
would obviate such a reaction. Since both antibodies
were of low titer, there is a possibility that they may
diminish over time. Together, these two adverse safety
findings precluded us continuing the study to test for
protective immunity against virulent parasite
challenge.
Conclusions
Although the results of this study overall do not support
the further clinical development of the P. falciparum
kahrp– strain as a blood-stage GAP malaria vaccine,
they do contribute valuable new information on the
pathogenicity of P. falciparum. Additionally, this study
acts as a proof-of-concept for the use of genetically
modified blood-stage malaria parasites in humans. We
have previously developed IBSM models for P. falcip-
arum [23], artemisinin-resistant P. falciparum [54], P.
vivax [55], and P. malariae [56]. The use of genetically
modified parasites in CHMI studies using the IBSM
model offers significant opportunities in the ongoing
search for interventions to reduce the burden of malaria.
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